Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
Background: We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson) in a broad group of patients and lesions.
Methods: Between May 21, 2007 and Dec 22, 2008, we recruited 8791 patients from 36 recruiting countries to participate in this open-label, multicentre, randomised, superiority trial. Eligible patients were those aged 18 years or older undergoing elective, unplanned, or emergency procedures in native coronary arteries. Patients were randomly assigned to either receive E-ZES and C-SES (ratio 1:1). Randomisation was stratified per centre with varying block sizes of four, six, or eight patients, and concealed with a central telephone-based or web-based allocation service. The primary outcome was definite or probable stent thrombosis at 3 years and was analysed by intention to treat. Patients and investigators were aware of treatment assignment. This trial is registered with ClinicalTrials.gov, number NCT00476957.
Findings: PROTECT randomised 8791 patients, of whom 8709 provided consent to participate and were eligible: 4357 were allocated to the E-ZES group and 4352 patients to the C-SES group. At 3 years, rates of definite or probable stent thrombosis did not differ between groups (1·4 for E-ZES [predicted: 1·5] vs 1·8 [predicted: 2·5] for C-SES; hazard ratio [HR] 0·81, 95 CI 0·58- 1·14, p=0·22). Dual antiplatelet therapy was used in 8402 (96) patients at discharge, 7456 (88) at 1 year, 3041 (37) at 2 years, and 2364 (30) at 3 years.
Interpretation: No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at 3 years. Time analysis suggests a difference in definite or probable stent thrombosis between groups is emerging over time, and a longer follow-up is therefore needed given the clinical relevance of stent thrombosis. Funding: Medtronic, Inc.
|Sponsor||Funding: Medtronic, Inc.|
|Persistent URL||dx.doi.org/10.1016/S0140-6736(12)61336-1, hdl.handle.net/1765/54482|
Camenzind, E, Wijns, W, Mauri, L, Kurowski, V, Parikh, K, Gao, R, … Steg, P.G. (2012). Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial. The Lancet, 380(9851), 1396–1405. doi:10.1016/S0140-6736(12)61336-1